Heterogeneous alteration of the ERBB3–MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient

Low-grade serous ovarian cancer (LGSOC) is relatively chemoresistant, and no precision therapy is approved for this indication. Despite promising results in phase II trials, MEK inhibitors have failed to show improved progression-free survival in a phase III trial when compared to physician's c...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, Ilaria, Garg, Swati, Danesh, Arnavaz, Bruce, Jeffrey, Shaw, Patricia, Tan, Qian, Quevedo, Rene, Braunstein, Marsela, Oza, Amit M., Pugh, Trevor, Lheureux, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913142/
https://www.ncbi.nlm.nih.gov/pubmed/31836588
http://dx.doi.org/10.1101/mcs.a004341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913142/
https://www.ncbi.nlm.nih.gov/pubmed/31836588
http://dx.doi.org/10.1101/mcs.a004341

Ejemplares similares